UNSPSC 51121907: Nesiritide

This classification denotes a nppb gene, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P7WI8UL647. European Medicines Agency schedules Nesiritide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12539MIG. Nesiritide generally arises in the molecular formula C143H244N50O42S4. The term NESIRITIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 no. 3, 1999, list 42.) Most nations schedule nesiritide under HS 29349990 and SITC 51579.

As of Q4 2014, NESIRITIDE remains the US FDA Preferred Term for this commodity. Nesiritide bears US NLM identifiers UMLS ID C0054015 and NCI Concept Code C47636.

UNSPSC 51121907 Nesiritide is a Commodity code covering emergency and critical-care medications supplied to state and local public health agencies, fire departments, and healthcare systems. State and local governments currently procure nesiritide and related advanced life support medications through sealed competitive bids and cooperative purchasing agreements, with demand driven by emergency medical services, hospital systems, and public health departments. The scope includes supply contracts specifying unit quantities, expiration-date requirements (typically nine months or more from acceptance), delivery timelines (often ten calendar days or less), quality warranties, and compliance with OSHA Hazard Communication Standards and FDA manufacturing requirements. Issuing bodies include city purchasing departments (represented by Tampa's fire rescue procurement) and state-level cooperative purchasing alliances serving multiple member jurisdictions. Small and local business enterprises receive set-aside consideration in some solicitations, such as Tampa's 5 percent bid discount for SLBE participation.

Recent activity spans Florida and multistate cooperative vehicles. The City of Tampa's Purchasing Department issued a sealed-bid solicitation (26P00188) due April 8, 2026, for Advanced Life Support Medications totaling an estimated $40,000 to supply Tampa Fire Rescue with labetalol, epinephrine, adenosine, and diltiazem vials. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with award effective July 1, 2026 and contract pricing weighted 75 percent on competitiveness. A Texas Health and Human Services Commission RFI (HHS0017013) posted April 3, 2026, sought vendor capabilities for direct-to-manufacturer prescription programs serving the state's pharmacy benefit system. Cooperative purchasing vehicles and state alliances represent the primary procurement mechanism for volume pharmaceutical supply across participating jurisdictions.